Brief: Almirall Says New Data Analysis On Tirbanibulin Shows Consistent Treatment Response For Actinic Keratosis
07/03/2025 11:32
March 7 (Reuters) - Almirall SA ALM.MC: NEW DATA ANALYSIS ON TIRBANIBULIN SHOWS CONSISTENT TREATMENT RESPONSE FOR ACTINIC KERATOSIS (AK) DATA FROM PHASE IV AND REAL-WORLD EVIDENCE STUDIES SHOW CONSISTENTLY HIGH LEVELS OF RESPONSE AS WELL AS PATIENT SATISFACTION Source text: ID:nBw6nHNTca Further company coverage: ALM.MC (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Almirall
See all newsBrief: Almirall Says Phase 3B Adlong Clinical Study Show Treatment Outcomes With Up To Five Years Of Lebrikizumab
Brief: Almirall And CrystalO To Discover, Develop Novel Small Molecules In Medical Dermatology
Almirall shares rise as lower costs beat EBITDA estimates
Brief: Almirall, Certest Biotec Sign Deal to Develop Rare Dermatology Treatments
Spanish stocks - Factors to watch on July 24